Current progress in dengue vaccines
详细信息    查看全文
  • 作者：Shu-Wen Wan (7) (8)
    Chiou-Feng Lin (7) (8) (9)
    Shuying Wang (7) (8)
    Yu-Hung Chen (7)
    Trai-Ming Yeh (8) (8)
    Hsiao-Sheng Liu (7) (8)
    Robert Anderson (7) (8) (9)
    Yee-Shin Lin (7) (8)
  • 关键词：Dengue ; Immunopathogenesis ; Vaccine
  • 刊名：Journal of Biomedical Science
  • 出版年：2013
  • 出版时间：December 2013
  • 年：2013
  • 卷：20
  • 期：1
  • 全文大小：249 KB
  • 参考文献：1. Simmons CP, Farrar JJ, Nguyen vV, Wills B: Dengue. / N Engl J Med 2012, 366:1423鈥?432. CrossRef
    2. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, / et al.: Dengue: a continuing global threat. / Nat Rev Microbiol 2010, 8:S7-S16. CrossRef
    3. Henchal EA, Putnak JR: The dengue viruses. / Clin Microbiol Rev 1990, 3:376鈥?96.
    4. Clyde K, Kyle JL, Harris E: Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. / J Virol 2006, 80:11418鈥?1431. CrossRef
    5. Chang CJ, Luh HW, Wang SH, Lin HJ, Lee SC, Hu ST: The heterogeneous nuclear ribonucleoprotein K (hnRNP K) interacts with dengue virus core protein. / DNA Cell Biol 2001, 20:569鈥?77. CrossRef
    6. Netsawang J, Noisakran S, Puttikhunt C, Kasinrerk W, Wongwiwat W, Malasit P, Yenchitsomanus PT, Limjindaporn T: Nuclear localization of dengue virus capsid protein is required for DAXX interaction and apoptosis. / Virus Res 2009, 147:275鈥?83. CrossRef
    7. Kaufmann B, Rossmann MG: Molecular mechanisms involved in the early steps of flavivirus cell entry. / Microbes Infect 2011, 13:1鈥?. CrossRef
    8. Winkler G, Maxwell SE, Ruemmler C, Stollar V: Newly synthesized dengue-2 virus nonstructural protein NS1 is a soluble protein but becomes partially hydrophobic and membrane-associated after dimerization. / Virology 1989, 171:302鈥?05. CrossRef
    9. Welsch S, Miller S, Romero-Brey I, Merz A, Bleck CK, Walther P, Fuller SD, Antony C, Krijnse-Locker J, Bartenschlager R: Composition and three-dimensional architecture of the dengue virus replication and assembly sites. / Cell Host Microbe 2009, 5:365鈥?75. CrossRef
    10. Flamand M, Megret F, Mathieu M, Lepault J, Rey FA, Deubel V: Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. / J Virol 1999, 73:6104鈥?110.
    11. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, Auethavornanan K, Jairungsri A, Kanlaya R, Tangthawornchaikul N, Puttikhunt C, / et al.: Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. / J Infect Dis 2006, 193:1078鈥?088. CrossRef
    12. Jacobs MG, Robinson PJ, Bletchly C, Mackenzie JM, Young PR: Dengue virus nonstructural protein 1 is expressed in a glycosyl-phosphatidylinositol-linked form that is capable of signal transduction. / FASEB J 2000, 14:1603鈥?610. CrossRef
    13. Noisakran S, Dechtawewat T, Avirutnan P, Kinoshita T, Siripanyaphinyo U, Puttikhunt C, Kasinrerk W, Malasit P, Sittisombut N: Association of dengue virus NS1 protein with lipid rafts. / J Gen Virol 2008, 89:2492鈥?500. CrossRef
    14. Somnuke P, Hauhart RE, Atkinson JP, Diamond MS, Avirutnan P: N-linked glycosylation of dengue virus NS1 protein modulates secretion, cell-surface expression, hexamer stability, and interactions with human complement. / Virology 2011, 413:253鈥?64. CrossRef
    15. Falgout B, Chanock R, Lai CJ: Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a. / J Virol 1989, 63:1852鈥?860.
    16. Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A: Inhibition of interferon signaling by dengue virus. / Proc Natl Acad Sci USA 2003, 100:14333鈥?4338. CrossRef
    17. Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat C, Panyim S, Katzenmeier G: Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation. / J Virol 2004, 78:13708鈥?3716. CrossRef
    18. Zhang L, Mohan PM, Padmanabhan R: Processing and localization of Dengue virus type 2 polyprotein precursor NS3-NS4A-NS4B-NS5. / J Virol 1992, 66:7549鈥?554.
    19. Matusan AE, Pryor MJ, Davidson AD, Wright PJ: Mutagenesis of the Dengue virus type 2 NS3 protein within and outside helicase motifs: effects on enzyme activity and virus replication. / J Virol 2001, 75:9633鈥?643. CrossRef
    20. Benarroch D, Selisko B, Locatelli GA, Maga G, Romette JL, Canard B: The RNA helicase, nucleotide 5鈥?triphosphatase, and RNA 5鈥?triphosphatase activities of Dengue virus protein NS3 are Mg 2+ -dependent and require a functional Walker B motif in the helicase catalytic core. / Virology 2004, 328:208鈥?18. CrossRef
    21. Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, Garcia-Sastre A: Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. / J Virol 2005, 79:8004鈥?013. CrossRef
    22. Umareddy I, Chao A, Sampath A, Gu F, Vasudevan SG: Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA. / J Gen Virol 2006, 87:2605鈥?614. CrossRef
    23. Egloff MP, Decroly E, Malet H, Selisko B, Benarroch D, Ferron F, Canard B: Structural and functional analysis of methylation and 5鈥?RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5. / J Mol Biol 2007, 372:723鈥?36. CrossRef
    24. Ackermann M, Padmanabhan R: De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase. / J Biol Chem 2001, 276:39926鈥?9937. CrossRef
    25. Kittigul L, Pitakarnjanakul P, Sujirarat D, Siripanichgon K: The differences of clinical manifestations and laboratory findings in children and adults with dengue virus infection. / J Clin Virol 2007, 39:76鈥?1. CrossRef
    26. Gubler DJ: Dengue and dengue hemorrhagic fever. / Clin Microbiol Rev 1998, 11:480鈥?96.
    27. Srikiatkhachorn A, Green S: Markers of dengue disease severity. / Curr Top Microbiol Immunol 2009, 338:67鈥?2. CrossRef
    28. Martina BE, Koraka P, Osterhaus AD: Dengue virus pathogenesis: an integrated view. / Clin Microbiol Rev 2009, 22:564鈥?81. CrossRef
    29. Bandyopadhyay S, Lum LC, Kroeger A: Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. / Trop Med Int Health 2006, 11:1238鈥?255. CrossRef
    30. Murphy BR, Whitehead SS: Immune response to dengue virus and prospects for a vaccine. / Annu Rev Immunol 2011, 29:587鈥?19. CrossRef
    31. Barniol J, Gaczkowski R, Barbato EV, da Cunha RV, Salgado D, Martinez E, Segarra CS, Pleites Sandoval EB, Mishra A, Laksono IS, / et al.: Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. / BMC Infect Dis 2011, 11:106. CrossRef
    32. Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC: Immunopathogenesis of dengue virus infection. / J Biomed Sci 2001, 8:377鈥?88. CrossRef
    33. Green S, Rothman A: Immunopathological mechanisms in dengue and dengue hemorrhagic fever. / Curr Opin Infect Dis 2006, 19:429鈥?36. CrossRef
    34. Whitehorn J, Simmons CP: The pathogenesis of dengue. / Vaccine 2011, 29:7221鈥?228. CrossRef
    35. Yacoub S, Mongkolsapaya J, Screaton G: The pathogenesis of dengue. / Curr Opin Infect Dis 2013, 26:284鈥?89. CrossRef
    36. Guzman A, Isturiz RE: Update on the global spread of dengue. / Int J Antimicrob Agents 2010,36(Suppl 1): S40-S42. CrossRef
    37. Pandey BD, Morita K, Hasebe F, Parquet MC, Igarashi A: Molecular evolution, distribution and genetic relationship among the dengue 2 viruses isolated from different clinical severity. / Southeast Asian J Trop Med Public Health 2000, 31:266鈥?72.
    38. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A: Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. / J Infect Dis 2000, 181:2鈥?. CrossRef
    39. Cologna R, Rico-Hesse R: American genotype structures decrease dengue virus output from human monocytes and dendritic cells. / J Virol 2003, 77:3929鈥?938. CrossRef
    40. Leitmeyer KC, Vaughn DW, Watts DM, Salas R, Villalobos I, de C, Ramos C, Rico-Hesse R: Dengue virus structural differences that correlate with pathogenesis. / J Virol 1999, 73:4738鈥?747.
    41. de Borba L, Strottmann DM, de Noronha L, Mason PW, Dos Santos CN: Synergistic interactions between the NS3(hel) and E proteins contribute to the virulence of dengue virus type 1. / PLoS Negl Trop Dis 2012, 6:e1624. CrossRef
    42. Perng GC, Lei HY, Lin YS, Chokephaibulkit K: Dengue vaccines: challenge and confrontation. / World J of Vaccines 2011, 1:109鈥?30. CrossRef
    43. Halstead SB: Neutralization and antibody-dependent enhancement of dengue viruses. / Adv Virus Res 2003, 60:421鈥?67. CrossRef
    44. Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, Yeh TM, Chen SH, Liu CC, Lei HY: The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. / J Immunol 2006, 176:2825鈥?832.
    45. Ubol S, Phuklia W, Kalayanarooj S, Modhiran N: Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. / J Infect Dis 2010, 201:923鈥?35. CrossRef
    46. Ubol S, Halstead SB: How innate immune mechanisms contribute to antibody-enhanced viral infections. / Clin Vaccine Immunol 2010, 17:1829鈥?835. CrossRef
    47. Halstead SB, Mahalingam S, Marovich MA, Ubol S, Mosser DM: Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. / Lancet Infect Dis 2010, 10:712鈥?22. CrossRef
    48. Selin LK, Varga SM, Wong IC, Welsh RM: Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. / J Exp Med 1998, 188:1705鈥?715. CrossRef
    49. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G: Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. / Nat Med 2003, 9:921鈥?27. CrossRef
    50. Kurane I, Innis BL, Nimmannitya S, Nisalak A, Meager A, Janus J, Ennis FA: Activation of T lymphocytes in dengue virus infections. High levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of children with dengue. / J Clin Invest 1991, 88:1473鈥?480. CrossRef
    51. Mangada MM, Rothman AL: Altered cytokine responses of dengue-specific CD4 + T cells to heterologous serotypes. / J Immunol 2005, 175:2676鈥?683.
    52. Hatch S, Endy TP, Thomas S, Mathew A, Potts J, Pazoles P, Libraty DH, Gibbons R, Rothman AL: Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. / J Infect Dis 2011, 203:1282鈥?291. CrossRef
    53. Malavige GN, Huang LC, Salimi M, Gomes L, Jayaratne SD, Ogg GS: Cellular and cytokine correlates of severe dengue infection. / PLoS One 2012, 7:e50387. CrossRef
    54. Gagnon SJ, Ennis FA, Rothman AL: Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones. / J Virol 1999, 73:3623鈥?629.
    55. Rothman AL: Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. / Nat Rev Immunol 2011, 11:532鈥?43. CrossRef
    56. Espada-Murao LA, Morita K: Dengue and soluble mediators of the innate immune system. / Trop Med Health 2011, 39:53鈥?2. CrossRef
    57. Wan SW, Lin CF, Yeh TM, Liu CC, Liu HS, Wang S, Ling P, Anderson R, Lei HY, Lin YS: Autoimmunity in dengue pathogenesis. / J Formos Med Assoc 2013, 112:3鈥?1. CrossRef
    58. Anderson R, Wang S, Osiowy C, Issekutz AC: Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. / J Virol 1997, 71:4226鈥?232.
    59. King CA, Anderson R, Marshall JS: Dengue virus selectively induces human mast cell chemokine production. / J Virol 2002, 76:8408鈥?419. CrossRef
    60. Juffrie M, van Der Meer GM, Hack CE, Haasnoot K, Sutaryo J, Veerman AJ, Thijs LG: Inflammatory mediators in dengue virus infection in children: interleukin-8 and its relationship to neutrophil degranulation. / Infect Immun 2000, 68:702鈥?07. CrossRef
    61. Nascimento EJ, Silva AM, Cordeiro MT, Brito CA, Gil LH, Braga-Neto U, Marques ET: Alternative complement pathway deregulation is correlated with dengue severity. / PLoS One 2009, 4:e6782. CrossRef
    62. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M: Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. / J Immunol 1998, 161:6338鈥?346.
    63. Lin CF, Lei HY, Liu CC, Liu HS, Yeh TM, Wang ST, Yang TI, Sheu FC, Kuo CF, Lin YS: Generation of IgM anti-platelet autoantibody in dengue patients. / J Med Virol 2001, 63:143鈥?49. CrossRef
    64. Saito M, Oishi K, Inoue S, Dimaano EM, Alera MT, Robles AM, Estrella BD Jr, Kumatori A, Moji K, Alonzo MT, / et al.: Association of increased platelet-associated immunoglobulins with thrombocytopenia and the severity of disease in secondary dengue virus infections. / Clin Exp Immunol 2004, 138:299鈥?03. CrossRef
    65. Oishi K, Inoue S, Cinco MT, Dimaano EM, Alera MT, Alfon JA, Abanes F, Cruz DJ, Matias RR, Matsuura H, / et al.: Correlation between increased platelet-associated IgG and thrombocytopenia in secondary dengue virus infections. / J Med Virol 2003, 71:259鈥?64. CrossRef
    66. Falconar AK: The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin/adhesin proteins and binds to human endothelial cells: potential implications in haemorrhagic fever pathogenesis. / Arch Virol 1997, 142:897鈥?16. CrossRef
    67. Lin CF, Lei HY, Shiau AL, Liu CC, Liu HS, Yeh TM, Chen SH, Lin YS: Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. / J Med Virol 2003, 69:82鈥?0. CrossRef
    68. Falconar AK: Antibody responses are generated to immunodominant ELK/KLE-type motifs on the nonstructural-1 glycoprotein during live dengue virus infections in mice and humans: implications for diagnosis, pathogenesis, and vaccine design. / Clin Vaccine Immunol 2007, 14:493鈥?04. CrossRef
    69. Markoff LJ, Innis BL, Houghten R, Henchal LS: Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. / J Infect Dis 1991, 164:294鈥?01. CrossRef
    70. Chungue E, Poli L, Roche C, Gestas P, Glaziou P, Markoff LJ: Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. / J Infect Dis 1994, 170:1304鈥?307. CrossRef
    71. Lin YS, Yeh TM, Lin CF, Wan SW, Chuang YC, Hsu TK, Liu HS, Liu CC, Anderson R, Lei HY: Molecular mimicry between virus and host and its implications for dengue disease pathogenesis. / Exp Biol Med (Maywood) 2011, 236:515鈥?23. CrossRef
    72. Chuang YC, Lin YS, Liu CC, Liu HS, Liao SH, Shi MD, Lei HY, Yeh TM: Factors contributing to the disturbance of coagulation and fibrinolysis in dengue virus infection. / J Formos Med Assoc 2013, 112:12鈥?7. CrossRef
    73. Rothman AL: Dengue: defining protective versus pathologic immunity. / J Clin Invest 2004, 113:946鈥?51.
    74. van der Schaar HM, Wilschut JC, Smit JM: Role of antibodies in controlling dengue virus infection. / Immunobiology 2009, 214:613鈥?29. CrossRef
    75. Wahala WM, Silva AM: The human antibody response to dengue virus infection. / Viruses 2011, 3:2374鈥?395. CrossRef
    76. Kaufman BM, Summers PL, Dubois DR, Eckels KH: Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. / Am J Trop Med Hyg 1987, 36:427鈥?34.
    77. Schlesinger JJ, Brandriss MW, Walsh EE: Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. / J Gen Virol 1987,68(Pt 3): 853鈥?57. CrossRef
    78. Kaufman BM, Summers PL, Dubois DR, Cohen WH, Gentry MK, Timchak RL, Burke DS, Eckels KH: Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. / Am J Trop Med Hyg 1989, 41:576鈥?80.
    79. Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, Mongkolsapaya J, Screaton G: Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. / Proc Natl Acad Sci U S A 2010, 107:16922鈥?6927. CrossRef
    80. An J, Zhou DS, Zhang JL, Morida H, Wang JL, Yasui K: Dengue-specific CD8 + T cells have both protective and pathogenic roles in dengue virus infection. / Immunol Lett 2004, 95:167鈥?74. CrossRef
    81. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, Peters B, Prestwood TR, Sette A, Shresta S: A protective role for dengue virus-specific CD8 + T cells. / J Immunol 2009, 182:4865鈥?873. CrossRef
    82. Gil L, Lopez C, Lazo L, Valdes I, Marcos E, Alonso R, Gambe A, Martin J, Romero Y, Guzman MG, / et al.: Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4 + and CD8 + cells against viral encephalitis in mice. / Int Immunol 2009, 21:1175鈥?183. CrossRef
    83. Gil L, Lopez C, Blanco A, Lazo L, Martin J, Valdes I, Romero Y, Figueroa Y, Guillen G, Hermida L: The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. / Viral Immunol 2009, 22:23鈥?0. CrossRef
    84. Zompi S, Santich BH, Beatty PR, Harris E: Protection from secondary dengue virus infection in a mouse model reveals the role of serotype cross-reactive B and T cells. / J Immunol 2012, 188:404鈥?16. CrossRef
    85. Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E: Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans. / PLoS Negl Trop Dis 2012, 6:e1568. CrossRef
    86. Whitehead SS, Blaney JE, Durbin AP, Murphy BR: Prospects for a dengue virus vaccine. / Nat Rev Microbiol 2007, 5:518鈥?28. CrossRef
    87. Thomas SJ, Endy TP: Critical issues in dengue vaccine development. / Curr Opin Infect Dis 2011, 24:442鈥?50. CrossRef
    88. Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, Whitehead S, Natarajan R, Laughlin C: Report of an NIAID workshop on dengue animal models. / Vaccine 2010, 28:4229鈥?234. CrossRef
    89. Yauch LE, Shresta S: Mouse models of dengue virus infection and disease. / Antiviral Res 2008, 80:87鈥?3. CrossRef
    90. Zompi S, Harris E: Animal models of dengue virus infection. / Viruses 2012, 4:62鈥?2. CrossRef
    91. Blaney JE Jr, Sathe NS, Hanson CT, Firestone CY, Murphy BR, Whitehead SS: Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1. / Virol J 2007, 4:23. CrossRef
    92. Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, Partidos CD, Huang CY, Stinchcomb DT, Osorio JE: Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. / Vaccine 2012, 30:1513鈥?520. CrossRef
    93. Murrell S, Wu SC, Butler M: Review of dengue virus and the development of a vaccine. / Biotechnol Adv 2011, 29:239鈥?47. CrossRef
    94. Monath TP: Treatment of yellow fever. / Antiviral Res 2008, 78:116鈥?24. CrossRef
    95. Eckels KH, Dubois DR, Putnak R, Vaughn DW, Innis BL, Henchal EA, Hoke CH Jr: Modification of dengue virus strains by passage in primary dog kidney cells: preparation of candidate vaccines and immunization of monkeys. / Am J Trop Med Hyg 2003, 69:12鈥?6.
    96. Bhamarapravati N, Sutee Y: Live attenuated tetravalent dengue vaccine. / Vaccine 2000,18(Suppl 2): 44鈥?7. CrossRef
    97. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, King AD, Houng HS, Tang D, Scherer JM, Hoke CH Jr, Innis BL: Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. / Am J Trop Med Hyg 2003, 69:24鈥?1.
    98. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chokejindachai W, / et al.: Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. / Am J Trop Med Hyg 2002, 66:264鈥?72.
    99. Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, / et al.: Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. / Pediatr Infect Dis J 2004, 23:99鈥?09. CrossRef
    100. Sanchez V, Gimenez S, Tomlinson B, Chan PK, Thomas GN, Forrat R, Chambonneau L, Deauvieau F, Lang J, Guy B: Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). / Vaccine 2006, 24:4914鈥?926. CrossRef
    101. Thomas SJ, Eckels KH, Carletti I, De La Barrera R, Dessy F, Fernandez S, Putnak R, Toussaint JF, Sun W, Bauer K, / et al.: A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. / Am J Trop Med Hyg 2013, 88:73鈥?8. CrossRef
    102. Men R, Bray M, Clark D, Chanock RM, Lai CJ: Dengue type 4 virus mutants containing deletions in the 3鈥?noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. / J Virol 1996, 70:3930鈥?937.
    103. McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, Pierro DJ, Schmidt AC, Blaney JE Jr, Murphy BR, Whitehead SS: Phase I clinical evaluation of rDEN4Delta30鈥?00,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. / Am J Trop Med Hyg 2008, 79:678鈥?84.
    104. Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L Jr, Murphy BR: A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3鈥?untranslated region is highly attenuated and immunogenic in monkeys. / J Virol 2003, 77:1653鈥?657. CrossRef
    105. Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS: Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. / BMC Infect Dis 2004, 4:39. CrossRef
    106. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS: Genetically modified, live attenuated dengue virus type 3 vaccine candidates. / Am J Trop Med Hyg 2004, 71:811鈥?21.
    107. Durbin AP, Kirkpatrick BD, Pierce KK, Schmidt AC, Whitehead SS: Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. / Vaccine 2011, 29:7242鈥?250. CrossRef
    108. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE: 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. / Vaccine 2007, 25:2758鈥?765. CrossRef
    109. Barban V, Girerd Y, Aguirre M, Gulia S, Petiard F, Riou P, Barrere B, Lang J: High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. / Vaccine 2007, 25:2941鈥?950. CrossRef
    110. Vlaycheva LA, Chambers TJ: Neuroblastoma cell-adapted yellow fever 17D virus: characterization of a viral variant associated with persistent infection and decreased virus spread. / J Virol 2002, 76:6172鈥?184. CrossRef
    111. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, / et al.: Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. / J Virol 2004, 78:4761鈥?775. CrossRef
    112. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J: A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. / J Infect Dis 2010, 201:370鈥?77. CrossRef
    113. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH: Live-attenuated tetravalent fengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled Phase 1 trial of safety and immunogenicity. / Pediatr Infect Dis J 2011, 30:e9-e11. CrossRef
    114. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, Wartel A, Crevat D: Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. / Vaccine 2011, 29:3863鈥?872. CrossRef
    115. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, / et al.: Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. / Lancet 2012, 380:1559鈥?567. CrossRef
    116. Halstead SB: Dengue vaccine development: a 75% solution? / Lancet 2012, 380:1535鈥?536. CrossRef
    117. Putnak R, Barvir DA, Burrous JM, Dubois DR, D鈥橝ndrea VM, Hoke CH, Sadoff JC, Eckels KH: Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. / J Infect Dis 1996, 174:1176鈥?184. CrossRef
    118. Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, / et al.: An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. / Vaccine 2005, 23:4442鈥?452. CrossRef
    119. Jaiswal S, Khanna N, Swaminathan S: Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. / J Virol 2003, 77:12907鈥?2913. CrossRef
    120. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, Elkins R, Chanock R, Moss B, Lai CJ: Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. / Vaccine 2000, 18:3113鈥?122. CrossRef
    121. Konishi E, Fujii A: Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. / Vaccine 2002, 20:1058鈥?067. CrossRef
    122. Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, Mune M, Rosario D, Valdes K, Vazquez S, Martinez R, / et al.: Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. / Am J Trop Med Hyg 2003, 69:129鈥?34.
    123. Kelly EP, Greene JJ, King AD, Innis BL: Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. / Vaccine 2000, 18:2549鈥?559. CrossRef
    124. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, Harada KE, Putnak JR, Ivy JM, McDonell M, Bignami GS, / et al.: Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. / Vaccine 2010, 28:2705鈥?715. CrossRef
    125. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH: The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. / Vaccine 2011, 29:7267鈥?275. CrossRef
    126. Chin JF, Chu JJ, Ng ML: The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. / Microbes Infect 2007, 9:1鈥?. CrossRef
    127. Hermida L, Bernardo L, Martin J, Alvarez M, Prado I, Lopez C, Sierra Bde L, Martinez R, Rodriguez R, Zulueta A, / et al.: A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. / Vaccine 2006, 24:3165鈥?171. CrossRef
    128. Leng CH, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Lien SP, Yueh A, Hsiao KN, Lai LW, / et al.: A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. / Microbes Infect 2009, 11:288鈥?95. CrossRef
    129. Chen HW, Liu SJ, Li YS, Liu HH, Tsai JP, Chiang CY, Chen MY, Hwang CS, Huang CC, Hu HM, / et al.: A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates. / Arch Virol 2013. Epub ahead of print PubMed PMID: 23456422
    130. Chen HW, Liu SJ, Liu HH, Kwok Y, Lin CL, Lin LH, Chen MY, Tsai JP, Chang LS, Chiu FF, / et al.: A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. / Vaccine 2009, 27:1400鈥?409. CrossRef
    131. Chiang CY, Liu SJ, Tsai JP, Li YS, Chen MY, Liu HH, Chong P, Leng CH, Chen HW: A novel single-dose dengue subunit vaccine induces memory immune responses. / PLoS One 2011, 6:e23319. CrossRef
    132. Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM: Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibody. / Virology 2009, 392:103鈥?13. CrossRef
    133. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, Waiyaiya E, Tran HB, Cowper AE, Chotiyarnwong P, / et al.: An in-depth analysis of original antigenic sin in dengue virus infection. / J Virol 2011, 85:410鈥?21. CrossRef
    134. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E: Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo . / Virology 2012, 429:12鈥?0. CrossRef
    135. Henchal EA, Henchal LS, Schlesinger JJ: Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. / J Gen Virol 1988,69(Pt 8): 2101鈥?107. CrossRef
    136. Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, Huang YF, Chou HY, Huang JL, Shaio MF, Sytwu HK: Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice. / Vaccine 2003, 21:3919鈥?929. CrossRef
    137. Costa SM, Freire MS, Alves AM: DNA vaccine against the non-structural 1 protein (NS1) of dengue 2 virus. / Vaccine 2006, 24:4562鈥?564. CrossRef
    138. Costa SM, Azevedo AS, Paes MV, Sarges FS, Freire MS, Alves AM: DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice. / Virology 2007, 358:413鈥?23. CrossRef
    139. Falgout B, Bray M, Schlesinger JJ, Lai CJ: Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. / J Virol 1990, 64:4356鈥?363.
    140. Amorim JH, Diniz MO, Cariri FA, Rodrigues JF, Bizerra RS, Goncalves AJ, de Barcelos Alves AM, de Souza Ferreira LC: Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant. / Vaccine 2012, 30:837鈥?45. CrossRef
    141. Lin CF, Wan SW, Cheng HJ, Lei HY, Lin YS: Autoimmune pathogenesis in dengue virus infection. / Viral Immunol 2006, 19:127鈥?32. CrossRef
    142. Chen MC, Lin CF, Lei HY, Lin SC, Liu HS, Yeh TM, Anderson R, Lin YS: Deletion of the C-terminal region of dengue virus nonstructural protein 1 (NS1) abolishes anti-NS1-mediated platelet dysfunction and bleeding tendency. / J Immunol 2009, 183:1797鈥?803. CrossRef
    143. Srivastava AK, Putnak JR, Warren RL, Hoke CH Jr: Mice immunized with a dengue type 2 virus E and NS1 fusion protein made in Escherichia coli are protected against lethal dengue virus infection. / Vaccine 1995, 13:1251鈥?258. CrossRef
    144. Lu H, Xu XF, Gao N, Fan DY, Wang J, An J: Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice. / Mol Immunol 2013, 54:109鈥?14. CrossRef
  • 作者单位：Shu-Wen Wan (7) (8)
    Chiou-Feng Lin (7) (8) (9)
    Shuying Wang (7) (8)
    Yu-Hung Chen (7)
    Trai-Ming Yeh (8) (8)
    Hsiao-Sheng Liu (7) (8)
    Robert Anderson (7) (8) (9)
    Yee-Shin Lin (7) (8)

    7. Department of Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan
    8. Department of Medical Laboratory Science and Biotechnology, National Cheng Kung University Medical College, Tainan, Taiwan
    9. Departments of Microbiology & Immunology and Pediatrics, and Canadian Center for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada
  • ISSN：1423-0127
文摘
Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700